In: Transactions of The Royal Society of Tropical Medicine and Hygiene, 2001, vol. 95, no. 4, p. 441-448
|
In: Open Forum Infectious Diseases, 2015, vol. 3, no. 1, p. -
|
In: International Journal of Epidemiology, 2004, vol. 33, no. 5, p. 1092-1102
|
In: The Journal of Infectious Diseases, 2013, vol. 207, no. 5, p. 848-859
|
In: Transactions of The Royal Society of Tropical Medicine and Hygiene, 2001, vol. 95, no. 1, p. 67-71
|
In: Transactions of The Royal Society of Tropical Medicine and Hygiene, 2009, vol. 103, no. 1, p. 79-86
|
In: Transactions of The Royal Society of Tropical Medicine and Hygiene, 2002, vol. 96, no. 3, p. 318-323
|
In: Transactions of The Royal Society of Tropical Medicine and Hygiene, 2013, vol. 107, no. 11, p. 672-683
|
In: International Journal of Epidemiology, 2015, vol. 44, no. 1, p. 87-97
|
In: Trends in Parasitology, 2015, vol. 31, no. 2, p. 46–51
Currently available drugs for Chagas’ disease are limited by toxicity and low efficacy in the chronic stage. Posaconazole, the most advanced new anti-chagasic drug candidate, did not fully confirm its initial potential in a Phase II clinical trial for chronic Chagas’ disease. Given that posaconazole is highly active against Trypanosoma cruzi in vitro, and was very well tolerated in clinical...
|